🇪🇺 Mogamulizumab-Kpkc in European Union

EMA authorised Mogamulizumab-Kpkc on 22 November 2018

Marketing authorisation

EMA — authorised 22 November 2018

  • Application: EMEA/H/C/004232
  • Marketing authorisation holder: Kyowa Kirin Holdings B.V.
  • Local brand name: Poteligeo
  • Indication: Poteligeo is indicated for the treatment of adult patients with mycosis fungoides (MF) or Sézary syndrome (SS) who have received at least one prior systemic therapy.
  • Pathway: orphan
  • Status: approved

Read official source →

Mogamulizumab-Kpkc in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Oncology approved in European Union

Frequently asked questions

Is Mogamulizumab-Kpkc approved in European Union?

Yes. EMA authorised it on 22 November 2018.

Who is the marketing authorisation holder for Mogamulizumab-Kpkc in European Union?

Kyowa Kirin Holdings B.V. holds the EU marketing authorisation.